Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia.
about
Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric DisordersMechanisms of granulin deficiency: lessons from cellular and animal modelsTherapeutic and diagnostic challenges for frontotemporal dementiaDiagnosis and management of behavioral variant frontotemporal dementiaEpigenetics of Alzheimer's disease and frontotemporal dementiaProgranulin: at the interface of neurodegenerative and metabolic diseasesProgranulin, a glycoprotein deficient in frontotemporal dementia, is a novel substrate of several protein disulfide isomerase family proteinsInactivation of CDK/pRb pathway normalizes survival pattern of lymphoblasts expressing the FTLD-progranulin mutation c.709-1G>AThe advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier)Targeted manipulation of the sortilin-progranulin axis rescues progranulin haploinsufficiencyIdentification and characterization of a novel DGAT1 missense mutation associated with congenital diarrheaProgranulin protein levels are differently regulated in plasma and CSF.Progranulin transcripts with short and long 5' untranslated regions (UTRs) are differentially expressed via posttranscriptional and translational repression.Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity.Insights into neuroepigenetics through human histone deacetylase PET imaging.Histone deacetylase inhibitor upregulates peroxisomal fatty acid oxidation and inhibits apoptotic cell death in abcd1-deficient glial cells.HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.Progranulin: a growth factor, a novel TNFR ligand and a drug targetEffects of Exercise on Progranulin Levels and Gliosis in Progranulin-Insufficient MiceTrehalose upregulates progranulin expression in human and mouse models of GRN haploinsufficiency: a novel therapeutic lead to treat frontotemporal dementia.Progranulin and Its Related MicroRNAs after Status Epilepticus: Possible Mechanisms of Neuroprotection.Progranulin: a proteolytically processed protein at the crossroads of inflammation and neurodegeneration.Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury.Epigenetic mechanisms in neurological diseaseStructural and functional brain connectivity in presymptomatic familial frontotemporal dementia.Advances in understanding the molecular basis of frontotemporal dementia.Progranulin: an emerging target for FTLD therapies.Progranulin deficiency induces overactivation of WNT5A expression via TNF-α/NF-κB pathway in peripheral cells from frontotemporal dementia-linked granulin mutation carriers.Lateral Temporal Lobe: An Early Imaging Marker of the Presymptomatic GRN Disease?Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice.Acetyltransferases (HATs) as targets for neurological therapeuticsProgranulin Levels in Plasma and Cerebrospinal Fluid in Granulin Mutation Carriers.Promoter DNA methylation regulates progranulin expression and is altered in FTLD.Therapy and clinical trials in frontotemporal dementia: past, present, and future.Progranulin axis and recent developments in frontotemporal lobar degenerationFrontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.Progress in frontotemporal dementia research.Presymptomatic studies in genetic frontotemporal dementia.Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies.Imaging and fluid biomarkers in frontotemporal dementia.
P2860
Q26766487-1CA8095F-BB29-41EF-9931-7A9EDFC347A6Q26824221-D1512D90-19A5-4BCB-8162-BF7474B349A1Q26998919-D5ED9A20-2777-4835-B414-5497DAE7A3C3Q27006258-948579D4-ADC7-484F-9D64-D803023348F2Q27010153-BEB3E1E1-9A2B-48A7-8469-13FA1E249CA1Q27024421-187A766E-F74A-4E0B-BFB9-F5AC3DA146C7Q28477534-80141543-5AC9-4458-BA27-3522CD03FA70Q28483833-BE29F8F3-96E2-4314-AFD9-A9D287059AC3Q28485924-EF9FC242-DDF1-4B31-B08A-EAFC5648915FQ28587955-1FDDE673-0FD3-4BAB-BAFC-221846A973E2Q33754253-24EE153C-C3BA-4501-A770-1F36C6226A86Q33927199-EF8C11CF-02D6-429C-A5C6-6AEFCADA1816Q34170826-907D0A03-92D4-49BE-9694-6D13C8E1FE01Q34329880-31912323-470B-4A95-A850-9DD631E59E61Q34536980-14E58972-8CBC-4308-9CE2-1B6E5BFD29D7Q34907267-26A3516F-CF67-474B-9175-EEE8EB379BC2Q35380239-E364AF97-EAAF-4186-8364-BFC23DA0CC9BQ35601050-5EA2D21E-1BF1-4223-965E-C6016CBAA510Q36036743-181FD391-4E6C-4D3D-8868-458D419F4CE3Q36061223-AB3DEBF7-3AB6-4516-BB07-8E4DF118CEFAQ36293051-F300E7AF-8757-401F-A927-2A103FD16740Q36294670-A36A412E-D1B1-4579-9FC3-A292EF21DB2FQ36357853-4E48AE12-553D-4089-BA3F-9DF6884E67AEQ36682567-88E50E56-ED48-42FA-BA39-BE70E0A19E1AQ36687146-42F04C15-AA1C-41CF-A7BE-5A1D4E483BDEQ36775677-951A83A5-1C1B-4417-B0A6-0C2E950204FAQ36826623-FEFD5A48-76CA-4F7F-9FEB-CE9AC47120DDQ37026304-A6CC5E17-DA35-42E7-A4A6-14681EB5B4F9Q37044191-110A9578-4110-410F-906C-B4F4FFC81FCEQ37087755-C637D982-A1C6-4919-8E11-96873E6F64E2Q37249167-7BC3B1E0-7AF3-468A-9422-AC51FFEEC891Q37293615-5CED44D5-D1D4-406E-84ED-EB932EA45884Q37485657-E606D8E7-7130-4706-B7A9-A1593ED17C67Q37566888-861C603B-5EE9-4166-8CAA-5F0E321BD74FQ37978700-599E24BF-339F-4A4C-AA9D-38DACA5D27E7Q38040822-D1ADB733-5362-4439-BCB8-0A653A299B49Q38065721-42CE924A-D085-4013-985F-429A88ED26B9Q38135140-B98C44D7-E83B-444A-AA04-DA824B106551Q38625515-C3A9689C-D88E-4D40-ADC7-071412E894A7Q38670219-BBA97E90-CDF5-448B-ACC8-F92C6592FF16
P2860
Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Suberoylanilide hydroxamic aci ...... ch to frontotemporal dementia.
@ast
Suberoylanilide hydroxamic aci ...... ch to frontotemporal dementia.
@en
type
label
Suberoylanilide hydroxamic aci ...... ch to frontotemporal dementia.
@ast
Suberoylanilide hydroxamic aci ...... ch to frontotemporal dementia.
@en
prefLabel
Suberoylanilide hydroxamic aci ...... ch to frontotemporal dementia.
@ast
Suberoylanilide hydroxamic aci ...... ch to frontotemporal dementia.
@en
P2093
P2860
P356
P1476
Suberoylanilide hydroxamic aci ...... ch to frontotemporal dementia.
@en
P2093
Basar Cenik
Bruce A Posner
Chantelle F Sephton
Colleen M Dewey
Daniel R Dries
Fen-Biao Gao
Giovanni Coppola
Joachim Herz
Kimberley Yu
P2860
P304
16101-16108
P356
10.1074/JBC.M110.193433
P407
P577
2011-03-23T00:00:00Z